A Phase 3 interventional study of Liraglutide 3.0 mg and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 54 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 7th largest by enrollment, is one of 12 that started in 2017, is one of 17 in phase 3, and was the 34th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 396 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 44th largest by enrollment of the 166 interventional ones that give a count, is one of 7 that started in 2017, is one of 62 in phase 3, and was the 26th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 396 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Diagnosed with type 2 diabetes mellitus - Treatment with up to 2 OADs (oral anti-diabetic) (metformin, glitazone, SGLT-2 inhibitor (sodium-glucose cotransporter-2 inhibitors) or sulphonylurea) - Stable treatment with basal insulin according to its label (no requirement of minimum or maximum dose) for at least 90 days prior to screening, as judged by the investigator - (glycosylated ) 6.0-10.0% (both inclusive) - (body mass index) equal to or above 27 kg/m\^2 - Age at least 18 years at the time of signing informed consent Exclusion Criteria: - Diagnosis of type 1 diabetes - Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 (see Section 8.2.3) - Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator - Unable or unwilling to perform self-monitoring of plasma glucose according to the protocol and to keep a diabetes diary - Treatment with any hypoglycaemic medications other than OADs and basal insulin within the past 90 days prior to screening - Treatment with a DPP-IV (dipeptidyl peptidase-4) inhibitor within the past 90 days prior to screening - Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure ( class III, IV), or second degree or greater heart block - Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) - Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measure as required by local regulation or practice) - For Germany: Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner - Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral , second generation antipsychotics) - History of pancreatitis (acute or chronic) - History of major depressive disorder within the past 2 years - Any lifetime history of a suicide attempt - Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to110 mmHg). - History of (except for non-melanoma skin cancer) within the past 5 years
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Liraglutide 3.0 mg
Drug: Placebo
Injected subcutaneously (s.c., under the skin) once daily
Injected subcutaneously (s.c., under the skin) once daily
Change in Body Weight (%)
Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 0, week 56
Participants Losing at Least 5% of Baseline Body Weight
The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 56
Participants Losing More Than 10% of Baseline Body Weight at Week 56
The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 56
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 0, week 56
Change in HbA1c
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 0, week 56
Change in FPG
Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 0, week 56
Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.
Time frame: Week 0, week 56
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score
Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
Time frame: Week 0, week 56
Change in Total Daily Insulin Dose (U)
Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)
Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Total Daily Basal Insulin Dose (U/kg)
Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Total Daily Insulin Dose (U/kg)
Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in 7-point SMPG Profile Mean Daytime Glucose Value
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in sBP and dBP
Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA
Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in SF-36: Sub-domains
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in SF-36: Physical Component Summary (PCS)
Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
Time frame: Week 0, week 56
Change in SF-36: Mental Component Summary (MCS)
Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
Time frame: Week 0, week 56
Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score
Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in IWQoL-Lite for CT: Psychosocial Domain Score
Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in IWQoL-Lite for CT: Total Score
Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Weight Related Sign and Symptom (WRSS) Measure, Categorical Responses
The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.
Time frame: Week 0, week 56
Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%
Percentage of participants who achieved HbA1c \<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia
Percentage of participants who achieved HbA1c \<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score
Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS
Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS
Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score
Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 56
Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0 to week 56 + 30 days
Number of Hypoglycaemic Episodes
Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0 to week 56 + 30 days
Change in Physical Examination
Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week -1, week 56
Change in Resting Pulse
Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week -1, week 56
Change in Electrocardiogram (ECG)
The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week -1, week 56
Change in Laboratory Measurements (Haematology) - Haemoglobin
Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Measurements (Haematology) - Haematocrit
Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Measurements (Haematology) - Erythrocytes
Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes
Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Albumin
Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase
Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea
Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine
Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein
Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - eGFR
Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Uric Acid
Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Calcitonin
Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone
Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
Time frame: Week 0, week 56
The trial was conducted at 53 sites in Canada (7), Germany (7), Israel (6), Italy (4), Mexico (2), Turkey (7) and United States (20).
| Milestone | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Started | 198 | 198 |
| Completed | 166 | 168 |
| Not completed | 32 | 30 |
| Withdrew: Adverse event | 15 | 6 |
| Withdrew: Protocol deviation | 6 | 6 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Other | 8 | 14 |
Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Percentage change | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -6.0 ± 6.0 | -1.5 ± 5.4 |
| On-drug observation period | -6.5 ± 5.8 | -1.7 ± 5.2 |
The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 51.80 | 23.98 |
| On-drug observation period | 56.92 | 21.83 |
The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \[AEs\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 22.77 | 6.55 |
| On-drug observation period | 22.56 | 5.58 |
Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Centimeters (cm) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -5.40 ± 6.06 | -2.60 ± 5.72 |
| On-drug observation period | -5.71 ± 6.05 | -2.78 ± 5.63 |
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Percentage of HbA1c | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -1.1 ± 1.2 | -0.5 ± 1.2 |
| On-drug observation period | -1.2 ± 1.1 | -0.7 ± 1.0 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Millimoles per liter (mmol/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | -0.91 ± 3.13 | -0.68 ± 3.04 |
| On-drug observation period | -1.05 ± 3.08 | -0.96 ± 2.68 |
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 2.5 ± 7.9 | 2.6 ± 7.3 |
| On-drug observation period | 2.9 ± 7.8 | 2.5 ± 7.1 |
Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| In-trial observation period | 7.3 ± 22.5 | 6.8 ± 21.5 |
| On-drug observation period | 8.2 ± 20.9 | 6.5 ± 21.8 |
Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Units of insulin dose (U) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Total Daily Insulin Dose (U) | 3 ± 30 | 18 ± 38 |
Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage change | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U) | 19 ± 121 | 64 ± 139 |
Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Units of insulin dose per kilogram(U/kg) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Total Daily Basal Insulin Dose (U/kg) | 0.05 ± 0.33 | 0.15 ± 0.30 |
Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| U/kg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Total Daily Insulin Dose (U/kg) | 0.05 ± 0.33 | 0.18 ± 0.37 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in 7-point SMPG Profile Mean Daytime Glucose Value | -2.2 ± 2.6 | -1.6 ± 2.8 |
Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Millimeters of mercury (mmHg) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| sBP | -6 ± 14 | -2 ± 15 |
| dBP | -3 ± 9 | -1 ± 9 |
Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Total cholesterol | -0.12 ± 0.82 | 0.04 ± 0.69 |
| HDL cholesterol | 0.05 ± 0.17 | 0.03 ± 0.17 |
| LDL cholesterol | -0.08 ± 0.72 | 0.05 ± 0.57 |
| VLDL cholesterol | -0.09 ± 0.35 | -0.04 ± 0.33 |
| Triglycerides | -0.21 ± 0.89 | -0.08 ± 0.80 |
| Free fatty acids | -0.10 ± 0.27 | -0.06 ± 0.34 |
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Bodily Pain | 1.2 ± 8.3 | 1.2 ± 9.1 |
| General Health | 1.9 ± 7.8 | 0.3 ± 7.7 |
| Physical Functioning | 2.5 ± 7.9 | 2.6 ± 7.3 |
| Role-physical | 0.8 ± 7.7 | 0.9 ± 8.0 |
| Role Lim Emotion Prob | -1.2 ± 8.1 | -0.3 ± 8.2 |
| Mental Health | -1.1 ± 8.6 | -1.1 ± 7.5 |
| Social Functioning | -0.7 ± 7.7 | -0.6 ± 6.3 |
| Vitality | 1.0 ± 8.0 | -0.0 ± 7.7 |
Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in SF-36: Physical Component Summary (PCS) | 2.7 ± 7.5 | 2.2 ± 7.2 |
Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in SF-36: Mental Component Summary (MCS) | -1.9 ± 7.9 | -1.7 ± 6.8 |
Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score | 4.0 ± 22.1 | 4.6 ± 23.1 |
Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in IWQoL-Lite for CT: Psychosocial Domain Score | 5.4 ± 18.4 | 4.0 ± 16.7 |
Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Score on a scale | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in IWQoL-Lite for CT: Total Score | 5.7 ± 17.6 | 4.8 ± 16.6 |
The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Week 0: Joint pain — Almost always/Always | 11 | 5 |
| Week 0: Joint pain — Never/Almost never | 74 | 85 |
| Week 0: Joint pain — Often | 17 | 18 |
| Week 0: Joint pain — Rarely | 47 | 42 |
| Week 0: Joint pain — Sometimes | 49 | 46 |
| Week 56: Joint pain — Almost always/Always | 6 | 5 |
| Week 56: Joint pain — Never/Almost never | 95 | 75 |
| Week 56: Joint pain — Often | 12 | 17 |
| Week 56: Joint pain — Rarely | 35 | 39 |
| Week 56: Joint pain — Sometimes | 39 | 52 |
| Week 0: Shortness of breath — Almost always/Always | 0 | 0 |
| Week 0: Shortness of breath — Never/Almost never | 131 | 140 |
| Week 0: Shortness of breath — Often | 3 | 3 |
| Week 0: Shortness of breath — Rarely | 45 | 32 |
| Week 0: Shortness of breath — Sometimes | 19 | 21 |
| Week 56: Shortness of breath — Almost always/Always | 1 | 1 |
| Week 56: Shortness of breath — Never/Almost never | 137 | 111 |
| Week 56: Shortness of breath — Often | 5 | 3 |
| Week 56: Shortness of breath — Rarely | 28 | 46 |
| Week 56: Shortness of breath — Sometimes | 16 | 27 |
| Week 0: Heat sensitivity — Almost always/Always | 8 | 9 |
| Week 0: Heat sensitivity — Never/Almost never | 106 | 109 |
| Week 0: Heat sensitivity — Often | 13 | 16 |
| Week 0: Heat sensitivity — Rarely | 34 | 31 |
| Week 0: Heat sensitivity — Sometimes | 37 | 31 |
| Week 56: Heat sensitivity — Almost always/Always | 2 | 8 |
| Week 56: Heat sensitivity — Never/Almost never | 92 | 87 |
| Week 56: Heat sensitivity — Often | 12 | 13 |
| Week 56: Heat sensitivity — Rarely | 42 | 47 |
| Week 56: Heat sensitivity — Sometimes | 39 | 33 |
| Week 0: Sexual desire — Almost always/Always | 8 | 8 |
| Week 0: Sexual desire — Never/Almost never | 119 | 121 |
| Week 0: Sexual desire — Often | 13 | 13 |
| Week 0: Sexual desire — Rarely | 35 | 32 |
| Week 0: Sexual desire — Sometimes | 23 | 22 |
| Week 56: Sexual desire — Almost always/Always | 6 | 11 |
| Week 56: Sexual desire — Never/Almost never | 105 | 109 |
| Week 56: Sexual desire — Often | 18 | 11 |
| Week 56: Sexual desire — Rarely | 34 | 32 |
| Week 56: Sexual desire — Sometimes | 24 | 25 |
| Week 0: Heavy sweating — Almost always/Always | 2 | 5 |
| Week 0: Heavy sweating — Never/Almost never | 101 | 104 |
| Week 0: Heavy sweating — Often | 15 | 14 |
| Week 0: Heavy sweating — Rarely | 40 | 38 |
| Week 0: Heavy sweating — Sometimes | 40 | 35 |
| Week 56: Heavy sweating — Almost always/Always | 1 | 5 |
| Week 56: Heavy sweating — Never/Almost never | 98 | 92 |
| Week 56: Heavy sweating — Often | 7 | 16 |
| Week 56: Heavy sweating — Rarely | 51 | 48 |
| Week 56: Heavy sweating — Sometimes | 30 | 27 |
| Week 0: Low physical stamina — Almost always/Always | 2 | 8 |
| Week 0: Low physical stamina — Never/Almost never | 73 | 78 |
| Week 0: Low physical stamina — Often | 22 | 14 |
| Week 0: Low physical stamina — Rarely | 56 | 47 |
| Week 0: Low physical stamina — Sometimes | 45 | 49 |
| Week 56: Low physical stamina — Almost always/Always | 3 | 4 |
| Week 56: Low physical stamina — Never/Almost never | 77 | 65 |
| Week 56: Low physical stamina — Often | 15 | 19 |
| Week 56: Low physical stamina — Rarely | 57 | 56 |
| Week 56: Low physical stamina — Sometimes | 35 | 44 |
| Week 0: Foot pain — Almost always/Always | 5 | 7 |
| Week 0: Foot pain — Never/Almost never | 114 | 108 |
| Week 0: Foot pain — Often | 17 | 12 |
| Week 0: Foot pain — Rarely | 34 | 31 |
| Week 0: Foot pain — Sometimes | 28 | 38 |
| Week 56: Foot pain — Almost always/Always | 2 | 7 |
| Week 56: Foot pain — Never/Almost never | 106 | 88 |
| Week 56: Foot pain — Often | 15 | 14 |
| Week 56: Foot pain — Rarely | 29 | 39 |
| Week 56: Foot pain — Sometimes | 35 | 40 |
| Week 0: Trouble sleeping — Almost always/Always | 6 | 4 |
| Week 0: Trouble sleeping — Never/Almost never | 119 | 111 |
| Week 0: Trouble sleeping — Often | 11 | 10 |
| Week 0: Trouble sleeping — Rarely | 30 | 42 |
| Week 0: Trouble sleeping — Sometimes | 32 | 29 |
| Week 56: Trouble sleeping — Almost always/Always | 6 | 3 |
| Week 56: Trouble sleeping — Never/Almost never | 104 | 98 |
| Week 56: Trouble sleeping — Often | 15 | 14 |
| Week 56: Trouble sleeping — Rarely | 38 | 33 |
| Week 56: Trouble sleeping — Sometimes | 24 | 40 |
| Week 0: Back pain — Almost always/Always | 8 | 6 |
| Week 0: Back pain — Never/Almost never | 96 | 98 |
| Week 0: Back pain — Often | 13 | 8 |
| Week 0: Back pain — Rarely | 49 | 40 |
| Week 0: Back pain — Sometimes | 32 | 44 |
| Week 56: Back pain — Almost always/Always | 5 | 4 |
| Week 56: Back pain — Never/Almost never | 93 | 86 |
| Week 56: Back pain — Often | 13 | 11 |
| Week 56: Back pain — Rarely | 47 | 45 |
| Week 56: Back pain — Sometimes | 29 | 42 |
| Week 0: Low energy — Almost always/Always | 0 | 2 |
| Week 0: Low energy — Never/Almost never | 102 | 90 |
| Week 0: Low energy — Often | 19 | 12 |
| Week 0: Low energy — Rarely | 46 | 42 |
| Week 0: Low energy — Sometimes | 31 | 50 |
| Week 56: Low energy — Almost always/Always | 0 | 4 |
| Week 56: Low energy — Never/Almost never | 82 | 77 |
| Week 56: Low energy — Often | 16 | 16 |
| Week 56: Low energy — Rarely | 49 | 50 |
| Week 56: Low energy — Sometimes | 40 | 41 |
Percentage of participants who achieved HbA1c \<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5% | 39.9 | 13.6 |
Percentage of participants who achieved HbA1c \<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia | 10.1 | 3.5 |
Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score | 28.8 | 26.3 |
Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS | 37.9 | 31.3 |
Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS | 14.6 | 11.6 |
Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score | 25.3 | 24.2 |
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Adverse events | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Adverse Events (AEs) | 1223 | 1148 |
Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Hypoglycaemic episodes | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Number of Hypoglycaemic Episodes | 1538 | 1973 |
Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Abdomen (week -1) Normal | 165 | 169 |
| Abdomen (week -1) Abnormal, NCS | 25 | 25 |
| Abdomen (week -1) Abnormal CS | 5 | 3 |
| Abdomen (week 56) Normal | 167 | 160 |
| Abdomen (week 56) Abnormal, NCS | 15 | 24 |
| Abdomen (week 56) Abnormal, CS | 3 | 3 |
| Gastrointestinal System (week -1) Normal | 185 | 187 |
| Gastrointestinal System (week -1) Abnormal NCS | 10 | 10 |
| Gastrointestinal System (week -1) Abnormal CS | 0 | 0 |
| Gastrointestinal System (week 56) Normal | 175 | 177 |
| Gastrointestinal System (week 56) Abnormal NCS | 10 | 8 |
| Gastrointestinal System (week 56) Abnormal CS | 0 | 0 |
| Cardiovascular System (week-1) Normal | 183 | 182 |
| Cardiovascular System (week-1) Abnormal NCS | 10 | 15 |
| Cardiovascular System (week-1) Abnormal CS | 2 | 0 |
| Cardiovascular System (week 56) Normal | 178 | 175 |
| Cardiovascular System (week 56) Abnormal NCS | 6 | 12 |
| Cardiovascular System (week 56) Abnormal CS | 1 | 0 |
| Nervous System (week -1) Normal | 158 | 159 |
| Nervous System (week -1) Abnormal NCS | 26 | 25 |
| Nervous System (week -1) Abnormal CS | 11 | 13 |
| Nervous System (week 56) Normal | 150 | 149 |
| Nervous System (week 56) Abnormal NCS | 22 | 24 |
| Nervous System (week 56) Abnormal CS | 13 | 14 |
| General Appearance (week -1) Normal | 150 | 150 |
| General Appearance (week -1) Abnormal NCS | 39 | 36 |
| General Appearance (week -1) Abnormal CS | 6 | 11 |
| General Appearance (week 56) Normal | 156 | 151 |
| General Appearance (week 56) Abnormal NCS | 23 | 27 |
| General Appearance (week 56) Abnormal CS | 6 | 9 |
| Head, eyes, ENTand Neck (week -1) Normal | 176 | 182 |
| Head, eyes, ENTand Neck (week -1) Abnormal NCS | 17 | 13 |
| Head, eyes, ENTand Neck (week -1) Abnormal CS | 2 | 2 |
| Head, eyes, ENTand Neck (week 56) Normal | 168 | 173 |
| Head, eyes, ENTand Neck (week 56) Abnormal NCS | 15 | 12 |
| Head, eyes, ENTand Neck (week 56) Abnormal CS | 2 | 2 |
| Lymph Node Palpation (week -1) Normal | 195 | 197 |
| Lymph Node Palpation (week -1) Abnormal NCS | 0 | 0 |
| Lymph Node Palpation (week -1) Abnormal CS | 0 | 0 |
| Lymph Node Palpation (week 56) Normal | 185 | 186 |
| Lymph Node Palpation (week 56) Abnormal NCS | 0 | 0 |
| Lymph Node Palpation (week 56) Abnormal CS | 0 | 0 |
| Musculoskeletal System (week -1) Normal | 180 | 180 |
| Musculoskeletal System (week -1) Abnormal NCS | 13 | 16 |
| Musculoskeletal System (week -1) Abnormal CS | 2 | 1 |
| Musculoskeletal System (week 56) Normal | 171 | 171 |
| Musculoskeletal System (week 56) Abnormal NCS | 13 | 14 |
| Musculoskeletal System (week 56) Abnormal CS | 1 | 2 |
| Respiratory System (week -1) Normal | 192 | 192 |
| Respiratory System (week -1) Abnormal NCS | 3 | 3 |
| Respiratory System (week -1) Abnormal CS | 0 | 2 |
| Respiratory System (week 56) Normal | 183 | 185 |
| Respiratory System (week 56) Abnormal NCS | 2 | 0 |
| Respiratory System (week 56) Abnormal CS | 0 | 2 |
| Skin (week -1) Normal | 155 | 156 |
| Skin (week -1) Abnormal NCS | 36 | 33 |
| Skin (week -1) Abnormal CS | 4 | 8 |
| Skin (week 56) Normal | 150 | 149 |
| Skin (week 56) Abnormal NCS | 28 | 29 |
| Skin (week 56) Abnormal CS | 7 | 9 |
| Thyroid Gland (week -1) Normal | 183 | 187 |
| Thyroid Gland (week -1) Abnormal NCS | 10 | 7 |
| Thyroid Gland (week -1) Abnormal CS | 2 | 3 |
| Thyroid Gland (week 56) Normal | 180 | 178 |
| Thyroid Gland (week 56) Abnormal NCS | 5 | 6 |
| Thyroid Gland (week 56) Abnormal CS | 0 | 3 |
Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Beats/minute | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Resting Pulse | 2 ± 9 | -0 ± 9 |
The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Normal (week -1) | 113 | 133 |
| Abnormal NCS (week -1) | 78 | 60 |
| Abnormal CS (week -1) | 4 | 4 |
| Normal (week 56) | 118 | 126 |
| Abnormal NCS (week 56) | 62 | 57 |
| Abnormal CS (week 56) | 5 | 3 |
Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements (Haematology) - Haemoglobin | -0.1 ± 0.5 | -0.1 ± 0.6 |
Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Percentage of red blood cells | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements (Haematology) - Haematocrit | -0.4 ± 2.8 | -0.2 ± 3.0 |
Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| 10^12 cells per liter (10^12 cells/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Measurements (Haematology) - Erythrocytes | -0.07 ± 0.27 | -0.04 ± 0.28 |
Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| 10^9 cells/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Thrombocytes | 7 ± 45 | 7 ± 46 |
| Leukocytes | -0.22 ± 1.41 | -0.24 ± 1.28 |
Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Grams per deciliter (g/dL) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - Albumin | -0.1 ± 0.2 | -0.1 ± 0.2 |
Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Units per liter (U/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Alkaline Phosphatase | -1 ± 16 | -0 ± 15 |
| Alanine Aminotransferase | -5 ± 15 | -6 ± 18 |
| Amylase | 13 ± 73 | -1 ± 22 |
| Aspartate aminotransferase | -3 ± 11 | -3 ± 14 |
| Lipase | 30 ± 143 | -8 ± 47 |
Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| mmol/L | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Bicarbonate serum | 0 ± 2 | -0 ± 2 |
| Total Calcium | -0.00 ± 0.11 | -0.02 ± 0.14 |
| Potassium | -0.0 ± 0.5 | -0.0 ± 0.5 |
| Sodium | -1 ± 2 | -0 ± 3 |
| Urea | 0.1 ± 1.5 | 0.1 ± 1.4 |
Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Micromoles per liter (umol/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Total Bilirubin | 1.0 ± 3.9 | 0.6 ± 3.6 |
| Creatinine | -0.1 ± 8.7 | -0.2 ± 8.4 |
Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Milligrams per liter (mg/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein | -1.40 ± 8.02 | -1.29 ± 10.07 |
Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Milliliters per minute per 1.73m^2 | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - eGFR | 0 ± 13 | 1 ± 13 |
Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| mg/dL | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - Uric Acid | -0.2 ± 1.0 | -0.0 ± 0.9 |
Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Nanograms per liter (ng/L) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - Calcitonin | 0.0 ± 1.5 | 0.0 ± 1.4 |
Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.
| Milli-international units per liter | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone | -0.0842 ± 1.2233 | 0.1002 ± 0.9493 |
Collected over From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 3.0 mg | 0/195 (0%) | 16/195 (8.2%) | 162/195 (83.1%) |
| Placebo | 0/197 (0%) | 19/197 (9.6%) | 141/197 (71.6%) |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/195 | 0/197 |
| Atrial flutterCardiac disorders | 0/195 | 2/197 |
| Adenocarcinoma pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/195 | 0/197 |
| Amylase increasedInvestigations | 1/195 | 0/197 |
| Coronary artery diseaseCardiac disorders | 1/195 | 0/197 |
| DiverticulitisInfections and infestations | 1/195 | 0/197 |
| DiverticulumGastrointestinal disorders | 1/195 | 0/197 |
| Endometrial hyperplasiaReproductive system and breast disorders | 1/195 | 0/197 |
| Facial bones fractureInjury, poisoning and procedural complications | 1/195 | 0/197 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 1/195 | 0/197 |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 58/195 | 23/197 |
| DiarrhoeaGastrointestinal disorders | 45/195 | 30/197 |
| NasopharyngitisInfections and infestations | 42/195 | 36/197 |
| VomitingGastrointestinal disorders | 32/195 | 12/197 |
| HeadacheNervous system disorders | 29/195 | 29/197 |
| Upper respiratory tract infectionInfections and infestations | 24/195 | 29/197 |
| ConstipationGastrointestinal disorders | 28/195 | 17/197 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/195 | 24/197 |
| InfluenzaInfections and infestations | 12/195 | 22/197 |
| Decreased appetiteMetabolism and nutrition disorders | 19/195 | 5/197 |
| Age, Continuous(years) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 55.9 ± 11.3 | 57.6 ± 10.4 | 56.8 ± 10.9 |
| Sex: Female, Male(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 108 | 99 | 207 |
| Male | 90 | 99 | 189 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 29 | 72 |
| Not Hispanic or Latino | 155 | 169 | 324 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 3 | 5 | 8 |
| Black or African American | 17 | 11 | 28 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| White | 174 | 180 | 354 |
| Other | 0 | 2 | 2 |
| Body weight(Kilograms (kg)) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 100.6 ± 20.8 | 98.9 ± 19.9 | 99.7 ± 20.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from Feb 2017 to primary completion in Sep 2018, 19 months.
Results were first posted in Nov 2019, 1 year 2 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide